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S U M M A R Y
Background: The Middle East respiratory syndrome coronavirus (MERS-CoV) has been reported to have a
high case-fatality rate. Currently, there is no speciﬁc therapy or vaccine with proven effectiveness for
MERS-CoV infections.
Methods: A combination of ribavirin and interferon therapy was used for the treatment of ﬁve MERS-
CoV-positive patients. We reviewed the therapeutic schedule and the outcome of these patients.
Results: All patients were critically ill with acute respiratory distress syndrome treated with adjunctive
corticosteroids and were on mechanical ventilation at the time of initiation of therapy. The median time
from admission to therapy with ribavirin and interferon was 19 (range 10–22) days. None of the patients
responded to the supportive or therapeutic interventions and all died of their illness.
Conclusions: While ribavirin and interferon may be effective in some patients, our practical experience
suggests that critically ill patients with multiple comorbidities who are diagnosed late in the course of
their illness may not beneﬁt from combination antiviral therapy as preclinical data suggest. There is
clearly an urgent need for a novel effective antiviral therapy for this emerging global threat.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Since the discovery of Middle East respiratory syndrome
coronavirus (MERS-CoV), the virus has caused 163 cases of disease,
with a fatality rate of 43–50%.1,2 The disease was initially described
in a patient from Saudi Arabia in June 2012.3 MERS-CoV has caused
sporadic cases and clusters in families and healthcare settings.4–7
The best treatment option for the virus is not known. In view of the
high case-fatality rate and the potential global spread of the virus,
there is an urgent need to develop effective therapies for this
infection. In a recent review, based on therapies used for the
related severe acute respiratory syndrome (SARS) coronavirus, the
possible use of interferon and ribavirin was considered as a
therapeutic option.8 The purpose of this study was to describe the* Corresponding author. Tel.: +966 13 877 3524; fax: +966 13 877 3790.
E-mail addresses: jaffar.tawﬁq@aramco.com, jaltawﬁ@yahoo.com
(J.A. Al-Tawﬁq).
1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International S
http://dx.doi.org/10.1016/j.ijid.2013.12.003outcome of the use of a combination of interferon-a2b and
ribavirin in the management of ﬁve patients with MERS-CoV
infections.
2. Materials and methods
This was a retrospective observational study of ﬁve MERS-CoV-
positive patients who received a combination therapy of interfer-
on-a2b and ribavirin. We describe the therapeutic schedule, the
clinical course, clinical and laboratory parameters, and outcomes.
2.1. MERS-CoV testing
Either Dacron ﬂocked nasopharyngeal swabs or tracheal
aspirates were obtained from the patients, and these were
submitted to the Ministry of Health MERS-CoV laboratory for
MERS-CoV diagnosis. The clinical samples were screened at the
Ministry of Health laboratory using a real-time reverse transcrip-
tase PCR.9,10 Ampliﬁcation targeted both the upstream E protein
(upE gene) and open reading frame 1a (ORF1a) for MERS-CoV
testing, and a case was considered positive if both assays were
positive, as described previously (Fig. 1).5ociety for Infectious Diseases. Open access under CC BY-NC-SA license.
Figure 1. Median, minimum, and maximum values for amylase, lipase, and lactate
dehydrogenase (LDH).
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3.1. Case 1
A 62-year-old woman with diabetes, hypertension, and end-
stage renal disease (ESRD) on hemodialysis was admitted with
fever, cough, and respiratory failure of 3-day duration (table 1). She
tested positive for MERS-CoV by PCR. Baseline laboratory data are
shown in tables 2 and 3. On admission, the patient was started on
oseltamivir 75 mg once daily for 5 days and levoﬂoxacin 500 mgintravenous (IV) every 2 days for 15 days. Imipenem was added on
day 5 for 3 days. On day 21 after admission, she was started on
ribavirin for 5 days with a loading dose of 2000 mg via nasogastric
tube, followed by 400 mg per os (PO) every 8 h, one dose of
interferon-a2b 130 mg subcutaneously, and methylprednisolone
40 mg IV every 8 h for 1 day, then twice daily for 1 day, then daily
for 2 days. She had a mild rise in amylase and lipase (from 61 to 126
U/l and from 274 to 348 U/l, respectively). The patient remained
critically ill on mechanical ventilation requiring inotropic support.
She died 34 days after admission from respiratory and multi-organ
failure.
3.2. Case 2
A 58-year-old man with diabetes, hypertension, and ESRD on
hemodialysis was admitted with cough, fever, and hypoxemic
respiratory failure of 2-day duration. He tested positive for MERS-
CoV by PCR. Baseline laboratory data are shown in tables 2 and 3.
On admission, the patient was started on oseltamivir 75 mg once
daily for 5 days, levoﬂoxacin 500 mg IV every 2 days for 6 days, and
imipenem 250 mg IV twice daily for 7 days. On day 6, he was
prescribed methylprednisolone 60 mg IV every 6 h for 6 days, then
every 8 h for 1 day, then 40 mg every 12 h for 1 day, followed by a
prednisolone tapered dose for another 10 days. On day 13 after
admission, he was started on ribavirin for 5 days with a loading
dose of 2000 mg PO, followed by 400 mg every 8 h and two doses of
interferon-a2b 100 mg subcutaneously once per week. Two weeks
after the initiation of the therapy, platelets dropped from 408 to
43  109/l (Table 2). The patient remained on the ventilator for
more than 30 days. He died 35 days after admission from multi-
organ failure.
3.3. Case 3
A 63-year-old woman with a history of severe bronchial asthma
and obstructive sleep apnea (on continuous positive airway
pressure (CPAP)), with coronary artery disease, diabetes, hyper-
tension, and chronic kidney disease (estimated glomerular
ﬁltration rate 15.7 ml/min), was admitted with fever, cough, and
dyspnea of 3-day duration and a diagnosis of pneumonia. She
tested positive for MERS-CoV by PCR. Baseline laboratory data are
shown in tables 2 and 3. On admission, the patient was also started
on oseltamivir 75 mg once daily for 5 days, levoﬂoxacin 750 mg IV
every 2 days for 7 days, and imipenem 500 mg IV every 6 h for 8
days. On day 11, she was started on ribavirin for 5 days, with a
loading dose of 2000 mg via nasogastric tube followed by 600 mg
PO every 8 h, one dose of interferon-a2b 144 mg subcutaneously,
and prednisone 40 mg PO daily, tapered to 10 mg PO daily for 10
days. One week after initiation of the antiviral and steroid therapy,
serum creatinine, aspartate aminotransferase (AST) tables 2 and 3,
and amylase increased (from 0.6 to 2.9 mg/dl, from 6.3 to 20  109/
l, from 25 to 126 IU/l, and from 35 to 255 U/l, respectively). The
patient was diagnosed with pancreatitis and thus further
interferon and ribavirin was not given. The patient remained
critically ill on mechanical ventilation. She died 45 days after
admission from multi-organ failure.
3.4. Case 4
An 81-year-old man with a history of atrial ﬁbrillation, diabetes
mellitus, and hypertension was admitted with progressive
respiratory distress and hypoxemia with fever for 2 days. He
tested positive for MERS-CoV by PCR. Baseline laboratory data are
shown in tables 2 and 3. On the ﬁrst day of hospitalization, the
patient was started on oseltamivir 75 mg once daily for 6 days,
levoﬂoxacin 750 mg every 48 h for 5 days, and imipenem 250 mg
Table 1













Dialysis Other chronic conditions
1 62 F 78 Yes Yes Yes 8.5 HD No
2 58 M 52 Yes Yes Yes 15.8 HD No
3 63 F 96 Yes Yes Yes 15.7 No Asthma, obstructive
sleep apnea, coronary
artery disease
4 81 M 71 Yes Yes Yes 40.7 HD Atrial ﬁbrillation
5 24 M 58 No No Yes 12.8 HD End-stage renal disease
ClCr, creatinine clearance; F, female; M, male; HD, hemodialysis.
Table 2
Laboratory results of patients at baseline and at 1 and 2 weeks after the initiation of interferon and ribavirin therapy
Case 1 Case 2 Case 3 Case 4 Case 5
Serum creatinine, mg/dl Baseline 5.8 4.9 0.6 0.7 4.5
Week 1 3.9 5.4 2.9 0.7 3.5
Week 2 5.7 3.8 1.7 7.3
Week 3 0.7
Platelet count,  109/l Baseline 290 408 272 74 194
Week 1 166 239 408 163 160
Week 2 233 43 106 234
Week 3 85
Hemoglobin, g/dl Baseline 11.3 9.3 10.5 11.7 8.4
Week 1 9.3 10.2 10.7 10 8.1
Week 2 9.4 9.1 9.1 8.7
Week 3 8.7
WBC count,  109/l Baseline 12.9 5.5 6.3 9.5 32.1
Week 1 7.2 4.3 20 10.7 15.5
Week 2 25.5 2.7 5.1 28.6
Week 3 4.7
Lymphocytes (%) Baseline 13 17 8 8 4
Week 1 17 18 2 2 19
Week 2 3 62 3 4
Week 3 13
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on ribavirin for 9 days, with a loading dose of 2000 mg via
nasogastric tube followed by 800 mg via nasogastric tube every
8 h, two doses of interferon-a2b 100 mg subcutaneously once per
week on hospital days 20 and 27, and methylprednisolone 40 mg
IV every 8 h for 4 days, then 40 mg IV twice daily for 2 days, then
40 mg daily for 2 days (started on hospital day 22). Three weeks
after the initiation of therapy, his hemoglobin dropped (from 11.7
to 8.7 g/dl) (Table 2), while bilirubin increased (from 0.7 to 7.4 mg/
dl), suggestive of hemolysis. The patient died 52 days after
admission from multi-organ failure.
3.5. Case 5
A 24-year-old man with a history of ESRD on hemodialysis was
admitted with a febrile illness, a cough for 10 days, and respiratory
failure requiring mechanical ventilation. He tested positive for
MERS-CoV by PCR. Baseline laboratory data are shown in tables 2
and 3. On the ﬁrst day of hospitalization, the patient was started on
oseltamivir 75 mg once daily for 2 days and imipenem 250 mg IV
twice daily for 11 days. On day 19 of admission, he was started on
ribavirin for 11 days, with a loading dose of 2000 mg via
nasogastric tube, followed by 400 mg via nasogastric tube every
8 h, and two doses of interferon-a2b 100 mg subcutaneously once
per week on hospital days 19 and 26. On the same day he started
ribavirin, he was also started on methylprednisolone 40 mg IV
every 8 h for 4 days, then 40 mg IV twice daily for 2 days, and then
40 mg daily for 2 days. Two weeks after the initiation of therapy,
lipase increased (from 561 to 612 U/l). The patient died 32 days
after admission from multi-organ failure.4. Results
We reviewed the cases of ﬁve patients with MERS-CoV
(Table 1). Their median age was 62 (range 24–81) years. The
patients had chronic kidney disease and four were on maintenance
hemodialysis. There were three men and two women. All patients
tested negative for inﬂuenza. The median number of days from
admission to therapy with ribavirin and interferon was 19 (range
10–22) (Table 4). All patients received adjunctive corticosteroid
therapy for acute respiratory distress syndrome. Two patients
developed increased lipase after the initiation of therapy, but both
of them were given corticosteroids at the same time as antiviral
therapy. One patient (case 2) developed thrombocytopenia, with a
platelet count that dropped from 408 to 49  109/l (Tables 2 and 3)
and one patient had possible hemolysis (case 3). All patients had
severe disease with progressive respiratory failure, developed
multi-organ failure, and died a mean 39.6 (standard deviation 8.5)
days after admission. None of the patients had bacteremia or
fungemia during their hospital stay. Figure 1 shows the median,
minimum, and maximum values for amylase, lipase, and lactate
dehydrogenase (LDH) for all the patients before initiation of
therapy and at week1 and 2 after therapy initiation.
5. Discussion
Since the emergence of MERS-CoV in 2012, the virus has caused
a total of 163 cases of disease, with a high case-fatality rate of 43%.2
There is an urgent need for effective therapeutic agents. To date,
no data are available on the use of any agents for the therapy of
MERS-CoV-positive patients. In this report we have described the
Table 3
Hepatic and pancreatic enzymes of patients at baseline and at 1 and 2 weeks after the initiation of interferon and ribavirin therapy
Liver function testa Pancreatic enzymesb
Test Baseline Week 1 Week 2 Week 3 Test Baseline Week 1 Week 2
Case 1 ALP 123 62 119 Amylase 61 105 126
ALT 15 24 22
AST 20 27 34 Lipase 274 380 348
LDH 677 543 936
Total bilirubin 1 0.7 0.8
Case 2 ALP 93 75 Amylase <30 45
ALT 32 17
AST 27 10 Lipase 26 152
LDH 593 543
Total bilirubin 0.7 1.5
Case 3 ALP 41 74 Amylase 35 255
ALT 22 49
AST 25 126 Lipase 55 53
LDH 1102 1389
Total bilirubin 0.6 0.4
Case 4 ALP 342 293 269 548 Amylase 141 148 59
ALT 53 41 48 68
AST 161 79 64 125 Lipase 373 492 394
LDH 2342 1875 1214 995
Total bilirubin 0.7 1.2 3.4 7.4
Case 5 ALP 230 136 101 Amylase 75 96
ALT 83 47 17
AST 65 14 15 Lipase 561 612
LDH 762 384 547
Total bilirubin 3.9 1.1 1.2
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase.
a ALP, U/L; ALT, IU/L; AST, IU/L; LDH, IU/L; bilirubin, mg/dl.
b Amylase, U/L; lipase, U/L
Table 4
Days from admission to initiation of therapy or death
Patient Days to antiviral therapy Days to steroid therapy Days to death
1 21 21 34
2 22 6 35
3 10 0 15
4 19 19 53
5 18 18 33
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ribavirin.
The patients were treated during the initial phase of the Al-Hasa
outbreak in April and May 2013, a time at which the disease
epidemiology and clinical characteristics were not known. Hence,
there was an inevitable time lapse from admission to the initiation
of therapy. All patients were already on mechanical ventilation by
the time interferon and ribavirin therapy was instituted and all had
a fatal outcome. The patients received the therapy late in the
course of the disease, at a median of 19 (range 10–22) days after
admission. Late therapy may have contributed to the poor
outcome, in addition to the severity of the disease and the
multiple comorbidities of the patients.
The timing of initiation of antiviral therapy is critical in the
treatment of most viral infections. In the treatment of SARS-CoV, no
effect of oseltamivir or ribavirin was observed when these agents
were started 6–14 days after symptom onset.11–13 Early therapy
with ribavirin, within 48 h of hospitalization or after the diagnosis of
SARS, has been shown to be associated with better outcomes,
although the numbers of patients enrolled in these studies has been
small.7,14–17 In the treatment of inﬂuenza, oseltamivir therapy early
in the disease resulted in reduced mortality when this was started
not later than 8 days after the onset of symptoms.18 Early in vitro
studies showed that ribavirin and interferon have anti-MERS-CoV
activity.19 The in vitro activity of interferon was augmented by
the concomitant use of ribavirin.20 In a rhesus macaque model of
MERS-CoV infection, the combination of interferon-a2b and
ribavirin therapy was effective in limiting the disease and resultedin very mild radiographic evidence of pneumonia.21 The treatment
was given within 8 h after inoculation of the rhesus macaques.
Treated animals had lower levels of systemic and local proin-
ﬂammatory markers and fewer viral genome copies.21 Although
these preclinical data are promising, our report illustrates some of
the real world issues of dealing with a novel emerging viral infection.
Our patients were not diagnosed until a week into their illnesses, by
which time all ﬁve were on mechanical ventilation. They had
multiple comorbidities, which most likely adversely affected their
clinical outcomes. In addition, we had no serial virologic determi-
nation of MERS-CoV levels in airway secretions to shed light on the
possibility of virological clearance, virological failure, or clinical
failure of therapy.
In our small series, adverse effects from combination ribavirin
and interferon therapy were observed in three cases. These side
effects have been noted before.22 Two patients had pancreatic
enzyme elevation and one had signiﬁcant hemolysis. These
ﬁndings were complicated by the presence of abnormal laboratory
ﬁndings even before the initiation of combination therapy, so it is
difﬁcult to determine which side effects were due to disease
progression and which were due to the therapeutic drugs.
There is an urgent need for large-scale clinical trials to
determine the safest and most effective regime for the treatment
of this novel highly fatal emerging infection. While ribavirin and
interferon may show promise, their use needs to be prompt and
adverse effects monitored closely. This therapeutic approach
should be tested in careful clinical studies.
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